Journal September 25, 2026 6 min read

What Does the Research Say About DNA Methylation?

DNA methylation is a covalent epigenetic modification of cytosine, typically at CpG dinucleotides. This page summarises laboratory and clinical research on its measurement, its association with disease states, and its mo

peptides-pro Editorial

DNA methylation is the covalent addition of a methyl group to the 5-carbon position of cytosine, predominantly within CpG dinucleotides, forming 5-methylcytosine. It is the most studied epigenetic mark in mammalian genomes and is commonly quantified by bisulfite sequencing, which converts unmethylated cytosine to uracil while leaving 5-methylcytosine unchanged. The modification is written and maintained by DNA methyltransferases (DNMT1, DNMT3A, DNMT3B) and is read by methyl-CpG-binding domain proteins. It does not alter the primary sequence; it alters transcriptional competence.

The work described below centres on the DNMT enzyme family and on promoter CpG methylation as a regulator of cytokine, receptor and tumour-suppressor gene transcription.

Research Studies

DNA methylation and partial reprogramming across mammalian species and tissues

An integrative secondary analysis pooled five publicly available DNA methylation datasets from partial reprogramming experiments. The datasets spanned multiple mammalian species, tissues, cell types and combinations of Yamanaka factors. The authors framed the work around the hypothesis that epigenetic alterations, particularly changes in DNA methylation patterns, contribute to biological decline, and that partial reprogramming can modulate those patterns [2].

IFNG promoter CpG methylation and viral load in people with HIV

In a study of people with HIV (PWH), DNA methylation at the IFNG promoter was quantified by bisulfite sequencing in peripheral blood mononuclear cells. Participants were stratified by plasma HIV RNA: high (>5000 copies/µL, n=16), medium (500 to 4999 copies/µL, n=18), or undetectable (≤50 copies/µL, n=18). Corresponding IFNG mRNA was measured by qPCR. The authors hypothesised that plasma HIV RNA would track with epigenetic remodelling at the IFNG promoter, altering IFNG mRNA transcription [5].

IFNG promoter methylation study: participant stratification by plasma HIV RNA

Group	Plasma HIV RNA	n
High	>5000 copies/µL	16
Medium	500 to 4999 copies/µL	18
Undetectable	≤50 copies/µL	18

Vipr2 methylation and expression in an animal model of ADHD

This study examined mRNA expression and DNA methylation levels of the Vipr2 gene, which encodes vasoactive intestinal peptide receptor 2, in the brains of spontaneous hypertensive rats (SHRs), an animal model of ADHD. The authors noted that recent methylome analyses had shown peripheral DNA methylation levels in the human VIPR2 gene to correlate with ADHD symptoms, but that brain mRNA expression and DNA methylation levels of VIPR2 in ADHD were unknown. mRNA levels of Vipr2 and related genes were analysed in the prefrontal cortex, nucleus accumbens and other regions [6]. This finding is animal-only.

DNA methylation as a predictor of postprandial glycaemic response in chronic low back pain

A registered clinical study (NCT07734714) is designed to examine whether DNA methylation and functional protein levels predict postprandial glycaemic responses to standardised drinks, standardised meals and real-life meals in patients with chronic low back pain (CLBP). The rationale cites impaired glucose metabolism as an important CLBP comorbidity and notes a role for the insulin-like growth factor 1 (IGF1)/growth hormone (GH) axis in pain modulation [4].

Natural compounds as epigenetic modulators in gynaecological cancers

A synthesis of evidence on epigenetic alterations in ovarian, cervical and endometrial malignancies critically evaluated dietary and natural compounds as epigenetic modulators. The review describes aberrant DNA methylation, altered histone modifications, dysregulated non-coding RNAs and N⁶-methyladenosine (m⁶A) RNA remodelling as contributors to tumour heterogeneity, recurrence and therapeutic resistance. The authors state that direct evidence that natural compounds modulate m⁶A machinery in gynaecological cancers remains absent and is considered a knowledge gap [3].

Polyphenols and epigenetic regulation in neurodegenerative disease

A review examined epigenetic regulation in neurodegenerative diseases, including DNA methylation, histone modifications and non-coding RNA regulation, alongside oxidative stress, chronic inflammation, protein misfolding and impaired synaptic plasticity. Natural polyphenolic compounds were assessed as candidate neuroprotective interventions on the basis of multi-target properties [8].

Hederagenin, DNMT1 and Klotho methylation in diabetic kidney disease

Hederagenin is a naturally occurring pentacyclic triterpenoid found in several medicinal plants traditionally used for renal and metabolic disorders. A study reported that hederagenin attenuates renal senescence in diabetic kidney disease by inhibiting DNMT1-mediated Klotho DNA methylation; the authors noted that this epigenetic mechanism had not been fully elucidated [9].

Piperlongumine derivatives and DNMT3A-mediated methylation in prostate cancer

Fourteen novel 1,2,3-triazole-hybridised piperlongumine derivatives were synthesised through rational structural modification. The compounds were reported to exert multimodal antitumour effects in prostate cancer via MAPK pathway activation, poly-mechanistic apoptosis induction, and DNMT3A-mediated DNA methylation reduction [11].

Extracellular matrix and microvascularisation genes in the mare placenta

In the mare placenta, a study evaluated gene transcription and expression of enzymes regulating collagen deposition, including matrix metalloproteinases MMP2 and MMP9 and their inhibitors TIMP1 and others, in the context of extracellular matrix and microvascularisation regulation [10].

sORF-encoded microproteins as emerging regulators

A review describes short open reading frames (sORFs) in the human genome and their translational products, termed sORF-encoded microproteins or micropeptides, which have historically been overlooked in conventional genome annotation. Increasing evidence demonstrates their regulatory roles in human physiology and disease [12].

Tirzepatide-responsive refractory diabetes in Prader-Willi syndrome

A case report described an adult female with Prader-Willi syndrome (PWS) and diabetes mellitus. PWS results from loss of expression of paternally inherited genes in the 15q11.2-q13 region and is characterised by severe hypotonia and feeding difficulties in infancy, followed by hyperphagia in later childhood and adolescence, which without strict control of excessive eating behaviours ultimately leads to severe obesity associated with type 2 diabetes mellitus. The patient had a history of hypotonia, developmental delay, intellectual disability, hyperphagia and morbid obesity [1].

Polycystic ovary syndrome in type 1 diabetes

A cross-sectional comparative clinical study (NCT07490964) is designed to investigate pathogenic mechanisms behind functional hyperandrogenism in women with type 1 diabetes from a sex/gender-medicine and sexual dimorphism perspective. Functional ovarian hyperandrogenism, including polycystic ovary syndrome (PCOS), is described as very prevalent in women with type 1 diabetes, with pathogenic mechanisms remaining unclear. The study includes five groups of subjects [7].

If you are reading this for personal health reasons

The materials and compounds discussed on this page are sold for laboratory research only. We do not provide dosing, medical guidance, or recommendations for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.